Revenue Growth
TELA Bio reported revenue of $20.7 million for Q3 2025, representing 9% growth over the prior year, with contributions from both the U.S. and international markets.
Sales and Marketing Efficiency
Sales and marketing expenses improved as a percentage of revenue from 89.7% in Q1 to 73.6% in Q3, demonstrating increased operational efficiency.
OviTex and OviTex PRS Performance
Achieved a significant milestone of surpassing 100,000 implantations of OviTex and OviTex PRS combined globally.
LIQUIFIX Technology Growth
Marked best revenue quarter ever with LIQUIFIX, highlighted by 126% growth year-over-year with the user base.
Financial Enhancements
Refinanced and upsized debt facility from $40 million to $60 million and completed a $13 million equity offering, significantly bolstering financial resources.